SCHEMBL3537622

SCHEMBL3537622

CN(C)C1CCN(c2ccc3[nH]c(-c4n[nH]c5ccccc45)nc3c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 13/20 0.61
FLT1 P17948 12/20 0.61
ABL1 P00519 9/20 0.60
KDR P35968 3/20 0.49
PDGFRB P09619 1/20 0.49
BCR P11274 2/20 0.47
PDPK1 O15530 2/20 0.46
ITK Q08881 2/20 0.46
PLK4 O00444 1/20 0.46
CHEK1 O14757 1/20 0.46
AURKA O14965 1/20 0.46
CHUK O15111 1/20 0.46
JAK2 O60674 1/20 0.46
ROCK2 O75116 1/20 0.46
MAP4K4 O95819 1/20 0.46
PAK4 O96013 1/20 0.46
CHEK2 O96017 1/20 0.46
NTRK1 P04629 1/20 0.46
PRKCG P05129 1/20 0.46
INSR P06213 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3533949 0.94 ABL1 (0.67) FGFR1FLT1ABL1KDRBCR
SCHEMBL3540044 0.88 FGFR1 (0.54) FGFR1FLT1ABL1KDRBCR
SCHEMBL3540562 0.88 ABL1 (0.49) FGFR1FLT1ABL1KDRPDPK1
SCHEMBL3539963 0.87 FGFR1 (0.49) FGFR1FLT1ABL1KDRPDPK1
SCHEMBL3532399 0.87 FGFR1 (0.62) FGFR1FLT1ABL1KDRPDPK1
SCHEMBL3535846 0.87 ABL1 (0.66) FGFR1FLT1ABL1KDRBCR
SCHEMBL3540171 0.86 ABL1 (0.58) FGFR1FLT1ABL1KDRBCR
SCHEMBL3539544 0.84 FGFR1 (0.60) FGFR1FLT1ABL1KDRBCR
SCHEMBL3542332 0.84 ABL1 (0.55) FGFR1FLT1ABL1KDRBCR
SCHEMBL3538447 0.83 FGFR1 (0.69) FGFR1FLT1ABL1KDRBCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed
EP-1401831-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2004-03-31 EP disclosed
US-20030207883-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2003-11-06 US disclosed
WO-2003004488-A1 INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS CHIRON CORPORATION (US) 2003-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885ABL1 1/4885
US-20030207883-A1 Indazole benzimidazole compounds SLCO1B3, SLCO1B1, SLCO4C1 FGFR1 2175/4885FLT1 3562/4885ABL1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.